Navigation Links
Chimerix Honored With "2011 Southeast BIO Deal of the Year: Venture Capital Transaction" Award
Date:11/7/2011

DURHAM, N.C., Nov. 7, 2011 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, was presented with the "2011 SEBIO Deal of the Year: Venture Capital Transaction" award during a ceremony held at the conclusion of Southeast BIO's (SEBIO) 13th Annual Investor Forum on November 3, 2011.  Kenneth I. Moch, President and Chief Executive Officer, and Timothy W. Trost, Senior Vice President and Chief Financial Officer, accepted the award on behalf of Chimerix.

Chimerix was recognized for having raised a $45 million venture capital financing round earlier this year. Investors in the financing, which closed in February, were Alta Partners, Asset Management Company, Canaan Partners, Frazier Healthcare Ventures, Morningside Group, New Leaf Venture Partners, Pappas Ventures, and Sanderling Ventures.  Since inception, Chimerix has raised over $100 million from leading venture capital investors, in addition to $60 million in government funding. Chimerix is developing broad spectrum, oral antiviral therapies for the treatment of life-threatening diseases in immunocompromised patients, such as stem cell and solid organ transplant recipients, and as a biodefense countermeasure in the event of a smallpox release.

"Chimerix is proud to be recognized by SEBIO as a driving force in the region's life science industry," said Moch.  "This award is a reflection of the hard work and dedication of Chimerix's employees to advancing our antiviral clinical development programs."

About Southeast BIO

Southeast BIO (SEBIO) is a regional nonprofit organization that fosters the growth of the life sciences industry in the Southeastern United States through efforts that promote entrepreneurship and bring together companies, investors, universities, and support organizations active in the development of the industry.

About Chimerix

Chimerix is developing novel antiviral therapeutics with the potential to transform patient care in multiple settings, including transplant, oncology, acute care and global health.  

The company's lead candidate, CMX001, is a broad spectrum, oral antiviral agent being tested in ongoing placebo-controlled clinical trials and in open-label treatment protocols for the prophylaxis, preemption and treatment of double-stranded DNA (dsDNA) viruses, such as herpesviruses, adenoviruses, and orthopoxviruses. To date, more than 650 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols, including over 350 individuals who have received CMX001 under Emergency Investigational New Drug Applications (EINDs) or as part of the CMX001-350 Open-Label Study to help treat life-threatening dsDNA viral diseases for which there are no other therapeutic options.  

Clinical studies of CMX001 include an ongoing Phase 2 study of the prevention/control of CMV in adult hematopoietic stem cell transplant patients (CMX001-201); a Phase 2 study for the treatment of adenovirus infection in pediatric and adult hematopoietic stem cell transplant patients (AdV HALT Trial/CMX001-202); and an Open-Label Study (CMX001-350) for the treatment of dsDNA viral infections.  The Open-Label Study builds on Chimerix's extensive experience working with over 150 clinicians at over 80 leading institutions in the United States, Canada, Europe, and Israel who have sought CMX001 under EINDs for the treatment of immunocompromised patients.  

CMX001 is also being developed as a medical countermeasure in the event of a smallpox release, including the potential to provide an important therapeutic option for the 80 million people in the U.S. currently estimated to be immunocompromised and thus not candidates to receive a smallpox vaccine.  Chimerix has received federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases under Grant No. U01-A1057233 and from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.  

Chimerix's second clinical-stage antiviral compound CMX157, a potent nucleoside analogue with in vitro activity against HIV and hepatitis B (HBV), has the potential to directly address several limitations of current HIV therapies.  Chimerix is developing CMX157 for the treatment of HIV and HBV infections, including those caused by multi-drug resistant viruses.  A Phase 1 clinical study has been completed demonstrating that the compound is well tolerated and that the active antiviral, TFV-PP, was measurable in peripheral blood mononuclear cells (PBMCs) after a single dose and remained detectable for six days, indicating that it may be suitable for once-weekly dosing.  

Led by a world-class antiviral drug development team, Chimerix is also leveraging the company's extensive chemical library to pursue new treatments for hepatitis C virus, influenza, malaria and other global public health needs.  For additional information on Chimerix, please visit http://www.chimerix.com.


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
(Date:5/25/2016)... 2016  According to Kalorama Information, the world ... 2015.  Though these are challenging times in the ... success for companies that remain optimistic and seek ... growth prospects medical device companies spend a higher ... (R&D) than do companies in other industries.  Also, ...
Breaking Medicine Technology:
(Date:5/30/2016)... , ... May 30, 2016 , ... ... 6th, while Shaolin warrior 8-day-8 and 8-night special intensive summer training camp starts ... annual overnight summer camp offers families and children a fun and unique experience ...
(Date:5/29/2016)... Cary, North Carolina (PRWEB) , ... May 29, 2016 , ... ... KP-400L wide jaw clipper that has been available via Amazon.com. This new ... who have thick nails. , The jaw opening is approximately 4mm and the actual ...
(Date:5/29/2016)... ... May 29, 2016 , ... "With 30 unique self-animating web themed ... the style of their project," said Christina Austin - CEO of Pixel Film Studios. ... created exclusively for use in Final Cut Pro X. Pixel Film Studios’ minimalistic titles ...
(Date:5/28/2016)... ... 2016 , ... "Color Grading media can be time consuming but with FCPX ... said Christina Austin - CEO of Pixel Film Studios. , With the FCPX ... color grades to their footage. A LUT is a Lookup Table that contains a ...
(Date:5/28/2016)... ... May 28, 2016 , ... After a year and a half of planning the ... extraordinary event. The Multiple Pathways of Recovery Conference was held May 2 -4, 2016 ... and the United Kingdom came together to explore the many pathways individuals use to get ...
Breaking Medicine News(10 mins):